Chai Discovery, founded in San Francisco in 2024, builds AI models that predict and design molecules, including antibodies. It raised a $400 million Series C at a $3.8 billion valuation in July 2026, led by Index Ventures with Kleiner Perkins, Sequoia Capital and OpenAI among the backers.
At a glance
| Price from | Custom |
| Best for | Drugmakers licensing AI molecule design tools |
From Chai Discovery's own website.
What stands out
- Paid deployments with large drugmakers
- Strong investor base including OpenAI
Worth knowing
- Very young company
- No clinical assets disclosed
How it ranks
Chai Discovery is ranked 3rd of 10 in Best AI Drug Discovery Startups (Lister Score 94.6).
#3 in Best AI Drug Discovery Startups · Lister Score 94.6
Chai's platform is reported to be in paid use at Eli Lilly, Pfizer, Novartis and argenx..
| Rank | Best AI Drug Discovery Startups | Score |
|---|---|---|
| 1 | Isomorphic Labs | 97.1 |
| 2 | Xaira Therapeutics | 95.8 |
| 3 | Chai Discovery | 94.6 |
| 4 | Enveda | 93.3 |
| 5 | insitro | 92.0 |
| 6 | Formation Bio | 90.7 |
| 7 | Genesis Molecular AI | 89.4 |
| 8 | BigHat Biosciences | 88.1 |
| 9 | Terray Therapeutics | 86.7 |
| 10 | Cradle | 85.3 |
Frequently asked questions
How does Chai Discovery rank on Lister?
Chai Discovery is ranked 3rd of 10 in Best AI Drug Discovery Startups (Lister Score 94.6).
Appears in
Add this badge to your site
If you work at Chai Discovery, paste this code into your website to show where it ranks on Lister. The badge links to the ranking and updates within a day when the rank changes.